Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (100.0%)Treatment of Post-Punch Biopsy Bleeding in Apixaban-Treated Patients Using Self-Administered BXP154B
Phase 2
Completed
- Conditions
- Wound Bleeding
- Interventions
- Drug: BXP154BDrug: PlaceboProcedure: Punch Biopsy
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Bio 54, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT06205615
- Locations
- 🇺🇸
Accel Research Sites Network - DeLand, DeLand, Florida, United States
Treatment of Post-Punch Biopsy Bleeding in Anticoagulated Patients Using Self-Administered BXP154
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Bio 54, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT05837338
- Locations
- 🇺🇸
Accel Research Sites Network - DeLand, DeLand, Florida, United States
News
No news found